Literature DB >> 8870895

Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids.

L V Allen1, M A Erickson.   

Abstract

The stability of drugs commonly prescribed for use in oral liquid dosage forms but not commercially available as such was studied. Ketoconazole 20 mg/mL, metolazone 1 mg/mL, metronidazole 50 mg/mL, procainamide hydrochloride 50 mg/ mL, and spironolactone 25 mg/mL were prepared in a 1:1 mixture of Ora-Sweet and Ora-Plus (Paddock Laboratories), a 1:1 mixture of Ora-Sweet SF and Ora-Plus (Paddock Laboratories), and cherry syrup and placed in 120-mL polyethylene terephthalate bottles. The sources of the drugs were powder, capsules, and tablets. Six bottles were prepared per liquid; three were stored at 5 degrees C and three at 25 degrees C, all in the dark. A sample was removed from each bottle immediately after preparation and at intervals up to 60 days and analyzed for drug concentration by stability-indicating high-performance liquid chromatography. At least 93% of the initial drug concentration was retained in all the oral liquids for up to 60 days. There were no substantial changes in the appearance or odor of the liquids, or in the pH. Ketoconazole 20 mg/mL, metolazone 1 mg/mL, metronidazole 50 mg/mL, procainamide hydrochloride 50 mg/ mL, and spironolactone 25 mg/mL were stable for up to 60 days at 5 and 25 degrees C in three extemporaneously compounded oral liquids. INDEX TERMS: Anti-infective agents; Antifungals; Capsules; Cardiac drugs; Cherry syrup; Compounding; Containers; Diuretics; Incompatibilities; Ketoconazole; Liquids; Metolazone; Metronidazole; Polyethylene terephthalate; Powders; Procainamide hydrochloride; Spironolactone; Stability; Storage; Suspending agents; Tablets; Temperature; Vehicles.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8870895     DOI: 10.1093/ajhp/53.17.2073

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  6 in total

1.  Osmolality of Commonly Used Oral Medications in the Neonatal Intensive Care Unit.

Authors:  Dhara D Shah; Andriy Kuzmov; Dana Clausen; Anita Siu; Christine A Robinson; Katelin Kimler; Rachel Meyers; Pooja Shah
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

2.  Predictions of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition.

Authors:  Chandan Bhugra; Rama Shmeis; Steven L Krill; Michael J Pikal
Journal:  Pharm Res       Date:  2006-08-24       Impact factor: 4.200

3.  Palatability of liquid anti-infectives: clinician and student perceptions and practice outcomes.

Authors:  Stacy C Gee; Tracy M Hagemann
Journal:  J Pediatr Pharmacol Ther       Date:  2007-10

4.  Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis.

Authors:  Valter V Andrade-Neto; Karina M Rebello; Thais M Pereira; Eduardo Caio Torres-Santos
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

5.  Management of Trichomoniasis in the Setting of 5-Nitroimidazole Hypersensitivity.

Authors:  Olivia T Van Gerwen; Andres F Camino; Lorelei N Bourla; Davey Legendre; Christina A Muzny
Journal:  Sex Transm Dis       Date:  2021-08-01       Impact factor: 3.868

6.  Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation.

Authors:  Manasa Tatipalli; Vijay Kumar Siripuram; Tao Long; Diana Shuster; Galina Bernstein; Pierre Martineau; Kim A Cook; Rodrigo Cristofoletti; Stephan Schmidt; Valvanera Vozmediano
Journal:  Pharmaceutics       Date:  2021-06-08       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.